Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
The arm of this study evaluates possible GABA-A receptor target engagement effects of the
FDA-approved medication, transdermal flumazenil (added 4/2020, replaced clarithromycin), in
the setting of Parkinson's disease. Half of the subjects will receive transdermal flumazenil
for 7-10 days, and half will receive a placebo. [11C]Flumazenil GABA-A receptor PET imaging
will be used to assess target engagement effects.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Nicolaas Bohnen, MD, PhD
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)